| Followers | 52 |
| Posts | 14305 |
| Boards Moderated | 0 |
| Alias Born | 06/15/2014 |
Monday, November 11, 2024 5:46:38 PM
SD, good question. No question that I am somewhat unhappy/frustrated about PFE's price movement.
First let me say that I don't know what is really going on behind the scenes with Starboard, Bourla, and others in the boardroom, so I will confine my thoughts to other things. I will give an example at the end of this but no question PFE is out of favor with investors and that is also partly because many are chasing momentum stocks. Like you say, they had great earnings this past qtr and the next qtr will be great in comparison to the same qtr last year. They have been cutting expenses, which is good and have almost 60 drugs in either phase II or phase III trials. No question I should have taken some or all off the table when they hit $60 almost exactly 3 years ago, but dumb me.
In Feb, Mar, April of this year I bought BMY in the high 40's and low 50's. It proceeded to go down (looking like another PFE) and in July I bought more at $40. Well, BMY has turned it around in the last month and today, after ABBV announced that their schizo drug missed targets, the stock jumped to $60. For quite a while things looked just as dire for BMY. I guess my experience with BMY this year has not only given me hope for the future of PFE but kept me calm while watching it go down. So, right now, I am sticking with PFE (and sucking up the divvy in the meantime) assuming and thinking that its time will come. With all those drugs in trials some have to hit just as some will fail.
When I look at my Fidelity site and the research section on PFE I see most if not all analysts rating it highly (that does scare me a tiny bit) and they have a thing called Trefis Valuation Estimate (have no idea what that is) and it pegs fair value at this very instant at $36.22. That is about $10 higher than the stock closed today. I don't presume to know how to unlock the value there, but I definitely think there is more value in the company than $26 a share. Plus if we expect interest rates to continue to come down the 6%+ div should ultimately drive investors looking for yield into the stock. Hope this didn't sound to rosy. I guess you didn't catch me on a bad day. Are your thoughts on PFE much different?
First let me say that I don't know what is really going on behind the scenes with Starboard, Bourla, and others in the boardroom, so I will confine my thoughts to other things. I will give an example at the end of this but no question PFE is out of favor with investors and that is also partly because many are chasing momentum stocks. Like you say, they had great earnings this past qtr and the next qtr will be great in comparison to the same qtr last year. They have been cutting expenses, which is good and have almost 60 drugs in either phase II or phase III trials. No question I should have taken some or all off the table when they hit $60 almost exactly 3 years ago, but dumb me.
In Feb, Mar, April of this year I bought BMY in the high 40's and low 50's. It proceeded to go down (looking like another PFE) and in July I bought more at $40. Well, BMY has turned it around in the last month and today, after ABBV announced that their schizo drug missed targets, the stock jumped to $60. For quite a while things looked just as dire for BMY. I guess my experience with BMY this year has not only given me hope for the future of PFE but kept me calm while watching it go down. So, right now, I am sticking with PFE (and sucking up the divvy in the meantime) assuming and thinking that its time will come. With all those drugs in trials some have to hit just as some will fail.
When I look at my Fidelity site and the research section on PFE I see most if not all analysts rating it highly (that does scare me a tiny bit) and they have a thing called Trefis Valuation Estimate (have no idea what that is) and it pegs fair value at this very instant at $36.22. That is about $10 higher than the stock closed today. I don't presume to know how to unlock the value there, but I definitely think there is more value in the company than $26 a share. Plus if we expect interest rates to continue to come down the 6%+ div should ultimately drive investors looking for yield into the stock. Hope this didn't sound to rosy. I guess you didn't catch me on a bad day. Are your thoughts on PFE much different?
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
